Loading
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, HCW9302, targets autoimmune conditions like alopecia areata and various metabolic disorders. Beyond these, HCW Biologics is also developing HCW9201, a cell-based therapy currently in Phase II clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. Additionally, HCW9206 is under development specifically for acute myeloid leukemia. Incorporated in 2018, the company's corporate headquarters are situated in Miramar, Florida.
Regular session
$2.50
+$0.04 · +1.63%
Regular session · ET · Market data may be delayed.
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, HCW9302, targets autoimmune conditions like alopecia areata and various metabolic disorders. Beyond these, HCW Biologics is also developing HCW9201, a cell-based therapy currently in Phase II clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. Additionally, HCW9206 is under development specifically for acute myeloid leukemia. Incorporated in 2018, the company's corporate headquarters are situated in Miramar, Florida.
Day range
Current $2.50
52-week range
Current $2.50
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
46
Fair Value
Sentiment
61
Bullish
Risk
80
High Risk
Momentum
17
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, HCW9302, targets autoimmune conditions like alopecia areata and various metabolic disorders. Beyond these, HCW Biologics is also developing HCW9201, a cell-based therapy currently in Phase II clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. Additionally, HCW9206 is under development specifically for acute myeloid leukemia. Incorporated in 2018, the company's corporate headquarters are situated in Miramar, Florida.
Day range
Current $2.50
52-week range
Current $2.50
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 54.23K USD | 2.57M USD | 2.84M USD | 6.72M USD | — |
| Cost of goods sold | 43.39K USD | 1.61M USD | 2.28M USD | 4.14M USD | — |
| Gross profit | 10.85K USD | 959.4K USD | 560.36K USD | 2.59M USD | — |
| Research and development | 5.44M USD | 6.39M USD | 7.68M USD | 9.34M USD | 8.17M USD |
| Selling, general, and administrative | 7.7M USD | 21.95M USD | 13.08M USD | 7.99M USD | 5.3M USD |
| Operating expenses | 11.27M USD | 30.44M USD | 26.28M USD | 17.67M USD | 13.37M USD |
| Interest income | — | — | — | — | 505.37K USD |
| Interest expense | 1.25M USD | 1.16M USD | 283.04K USD | 126.66K USD | — |
| Depreciation and amortization | 1.04M USD | 1.18M USD | 1.14M USD | 717.85K USD | 543.6K USD |
| Operating income | −11.26M USD | −29.48M USD | −25.72M USD | −15.08M USD | −13.37M USD |
| Net income | −7.96M USD | −30.02M USD | −24.99M USD | −14.9M USD | −12.86M USD |
Company facts updated Sep 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
